The functional activity of B7-H6, a protein crucial for natural killer (NK) cell-mediated cytotoxicity against tumor cells, can be influenced by various compounds that enhance the immune response, particularly involving NK cells. Interleukin-2 (IL-2) and Interleukin-15 (IL-15) are cytokines that stimulate NK cell activity, potentially augmenting the immune response mediated by B7-H6 and NKp30 interaction. IL-2 and IL-15 can increase the proliferation and activation of NK cells, thereby enhancing their ability to recognize and kill B7-H6-expressing tumor cells.
Immunomodulatory drugs like Lenalidomide, Thalidomide, and Pomalidomide can also enhance NK cell activity. These compounds can increase the expression of activating receptors on NK cells, thereby enhancing the NK cell response to B7-H6-expressing cells. Proteasome inhibitors like Bortezomib and Heat Shock Protein 90 (HSP90) inhibitors, such as 17-AAG, can induce stress in tumor cells, potentially leading to increased expression of B7-H6, making these cells more susceptible to NK cell-mediated killing.
Histone Deacetylase (HDAC) inhibitors, including Vorinostat, can influence gene expression in tumor cells and may upregulate B7-H6 expression. This upregulation can enhance the visibility of tumor cells to NK cells. Toll-Like Receptor (TLR) agonists, such as Imiquimod, activate the immune system and may also enhance the expression of ligands like B7-H6 on tumor cells.
Interferons, particularly IFN-alpha and IFN-gamma, are critical in enhancing NK cell activity and may upregulate B7-H6 expression on tumor cells, thus facilitating NK cell-mediated recognition and elimination of these cells. Additionally, monoclonal antibodies targeting NKp30 can specifically enhance the interaction between NK cells and B7-H6-expressing cells, boosting the NK cell-mediated immune response.
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
来那度胺能增强 NK 细胞的活性,并能增加 NK 细胞上活化受体的表达。这可能会增强 NK 细胞对 B7-H6 表达细胞的反应。 | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
沙利度胺能调节免疫系统,增强 NK 细胞的活性。这可能会提高 NK 细胞与 B7-H6 相互作用的有效性。 | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $98.00 $140.00 $306.00 $459.00 $1224.00 $1958.00 | 1 | |
泊马度胺可增强免疫反应,包括 NK 细胞的活性。这可能导致对表达 B7-H6 的细胞的反应增强。 | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
硼替佐米是一种蛋白酶体抑制剂,可诱导肿瘤细胞产生应激反应,从而可能上调 B7-H6 的表达,增强 NK 细胞介导的针对这些细胞的免疫反应。 | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
HSP90 抑制剂可诱导肿瘤细胞的应激反应,可能会上调 B7-H6 的表达,增强 NK 细胞对应激或恶性细胞的识别能力。 | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC 抑制剂可影响肿瘤细胞的基因表达,从而可能影响 B7-H6 的表达,增加这些细胞在 NK 细胞面前的可见度。 | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $66.00 $278.00 | 6 | |
TLR 激动剂可激活免疫系统,并可能增强肿瘤细胞上 B7-H6 等配体的表达,从而增加它们对 NK 细胞介导的细胞毒性的敏感性。 |